Comparative Pharmacology
Head-to-head clinical analysis: HYDROXOCOBALAMIN versus HYDROXOMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXOCOBALAMIN versus HYDROXOMIN.
HYDROXOCOBALAMIN vs HYDROXOMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxocobalamin is a precursor of methylcobalamin and adenosylcobalamin, which are essential cofactors for methionine synthase and methylmalonyl-CoA mutase. It facilitates the conversion of homocysteine to methionine and methylmalonyl-CoA to succinyl-CoA, and neutralizes cyanide by forming cyanocobalamin.
Hydroxocobalamin is a synthetic form of vitamin B12 that acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis. It also acts as a direct scavenger of cyanide ions by binding to them to form cyanocobalamin, which is excreted renally.
1000 mcg intramuscularly once daily for 1 week, then weekly for 1 month, then monthly. For maintenance: 1000 mcg intramuscularly once monthly. Route: IM.
100 mg intramuscularly or deep subcutaneously three times a week.
None Documented
None Documented
Terminal elimination half-life: ~26-31 days. After high-dose therapy, plasma levels decline more rapidly initially (α-phase half-life ~6 hours) due to distribution, followed by slow terminal elimination reflecting tissue release. Clinically, this supports monthly dosing for deficiency correction.
Terminal elimination half-life approximately 4-6 hours; may extend to 8-12 hours in moderate to severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion (50-90% as unchanged drug). Biliary/fecal elimination accounts for <10%.
Primarily renal (80-90% unchanged) with minor biliary/fecal elimination (5-10%); total clearance ~150 mL/min.
Category C
Category C
Vitamin B12 Supplement
Vitamin B12 Supplement